home / stock / vigl / vigl quote
Last: | $4.30 |
---|---|
Change Percent: | 0.0% |
Open: | $4.2 |
Close: | $4.30 |
High: | $4.4 |
Low: | $4.2 |
Volume: | 231,475 |
Last Trade Date Time: | 07/16/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$4.3 | $4.2 | $4.3 | $4.4 | $4.2 | 231,475 | 07-16-2024 |
$4.2 | $4.35 | $4.2 | $4.49 | $4.15 | 254,985 | 07-15-2024 |
$4.35 | $4.39 | $4.35 | $4.525 | $4.29 | 242,078 | 07-12-2024 |
$4.4 | $4.23 | $4.4 | $4.49 | $4.1 | 426,878 | 07-11-2024 |
$4.19 | $4.03 | $4.19 | $4.23 | $3.96 | 315,671 | 07-10-2024 |
$4 | $3.9 | $4 | $4.065 | $3.77 | 201,564 | 07-09-2024 |
$3.87 | $3.92 | $3.87 | $4.0799 | $3.79 | 388,444 | 07-08-2024 |
$4.03 | $4 | $4.03 | $4.07 | $3.82 | 273,902 | 07-05-2024 |
$3.95 | $4.04 | $3.95 | $4.14 | $3.9 | 239,799 | 07-04-2024 |
$3.95 | $4.04 | $3.95 | $4.14 | $3.9 | 239,799 | 07-03-2024 |
$4.005 | $4.27 | $4.005 | $4.2789 | $3.9001 | 408,328 | 07-02-2024 |
$4.37 | $4 | $4.37 | $4.4178 | $3.81 | 776,802 | 07-01-2024 |
$4 | $4.48 | $4 | $4.5686 | $4 | 2,676,868 | 06-28-2024 |
$4.48 | $4.48 | $4.48 | $4.77 | $3.7909 | 16,869,850 | 06-27-2024 |
$3.78 | $3.7 | $3.78 | $4 | $3.5909 | 149,237 | 06-26-2024 |
$3.72 | $3.88 | $3.72 | $3.915 | $3.51 | 191,778 | 06-25-2024 |
$3.88 | $3.96 | $3.88 | $4.15 | $3.87 | 116,420 | 06-24-2024 |
$3.86 | $4.19 | $3.86 | $4.2625 | $3.76 | 227,193 | 06-21-2024 |
$4.19 | $3.79 | $4.19 | $4.4 | $3.76 | 135,817 | 06-20-2024 |
$3.87 | $4.18 | $3.87 | $4.1865 | $3.66 | 179,471 | 06-19-2024 |
News, Short Squeeze, Breakout and More Instantly...
Vigil Neuroscience Inc. Company Name:
VIGL Stock Symbol:
NASDAQ Market:
Vigil Neuroscience Inc. Website:
2024-06-28 09:15:05 ET Wedbush analyst issues OUTPERFORM recommendation for VIGL on June 28, 2024 07:53AM ET. The previous analyst recommendation was Outperform. VIGL was trading at $4.48 at issue of the analyst recommendation. Historical Analyst Recommendations La...
- Sanofi to invest $40 million at an as-converted price of $7.44 per share of common stock- - Sanofi to receive an exclusive right of first negotiation for license of Company’s small molecule TREM2 agonist program, including VG-3927, currently in phase 1 clinical studies - ...